On July 17, Alibaba Health fell 3.17% in regular trading, trading at HK$3.34/share, with turnover of HK$125 million.

On the news front, the medical e-commerce sector weakened again, with peers JD Health down 5.05%, Ping An Good Doctor down 4.75%, and Meituan down 5.33%, creating broad-based selling pressure that weighed on Alibaba Health. UBS previously maintained its sell rating on the stock and lowered its target price to HK$3.1, with the current share price now closely approaching that level, keeping bearish expectations firmly in place.

On the capital flow side, southbound funds have cumulatively net sold over 128 million shares over the past 20 trading days, reflecting persistent institutional outflows that further exacerbated downside pressure. Within the Internet and Direct Marketing Retail sector, BABA-W fell 3.08%, Meituan-W fell 5.33%, JD-SW fell 0.26%, JD Health fell 5.0%, and PA Good Doctor fell 5.13%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)